| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6432440 | BTCP PHARMA | Pectin compositions and methods of use for improved delivery of drugs to mucosal surfaces |
Apr, 2018
(6 years ago) | |
| US9078814 | BTCP PHARMA | Intranasal spray device containing pharmaceutical composition |
Jan, 2024
(3 months ago) | |
| US9814705 | BTCP PHARMA | Intranasal spray device containing pharmaceutical composition |
Jan, 2024
(3 months ago) | |
| US8889176 | BTCP PHARMA | Method of managing or treating pain |
Jan, 2024
(3 months ago) | |
| US8216604 | BTCP PHARMA | Method of managing or treating pain |
Oct, 2024
(5 months from now) | |
| US9731869 | BTCP PHARMA | Container |
Jan, 2032
(7 years from now) | |
Lazanda is owned by Btcp Pharma.
Lazanda contains Fentanyl Citrate.
Lazanda has a total of 6 drug patents out of which 4 drug patents have expired.
Expired drug patents of Lazanda are:
- US6432440
- US9078814
- US9814705
- US8889176
Lazanda was authorised for market use on 30 June, 2011.
Lazanda is available in spray, metered;nasal dosage forms.
Lazanda can be used as management of breakthrough pain in cancer patients 18 years of age and older who are receiving and tolerant to opioid therapy for their underlying persistent cancer pain, management of breakthrough pain in patients with cancer.
The generics of Lazanda are possible to be released after 26 January, 2032.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Jun 30, 2014 |
Drugs and Companies using FENTANYL CITRATE ingredient
Market Authorisation Date: 30 June, 2011
Treatment: Management of breakthrough pain in cancer patients 18 years of age and older who are receiving and tolerant to opioid therapy for their underlying persistent cancer pain; Management of breakthrough pa...
Dosage: SPRAY, METERED;NASAL
LAZANDA family patents
